Setting of questionnaire completion | Â |
Hospital outpatient | 266 (70%) |
Hospital inpatient | 18 (4.7%) |
Participant’s home | 93 (24.5%) |
Other/not known | 3 (0.8%) |
Gender | Â |
Male | 231 (60.8%) |
Female | 149 (39.2%) |
Age | Â |
Median (range) | 69 (38–91) |
<65 | 113 (29.7%) |
≥65 | 267 (70.3%) |
Marital status | Â |
Single | 33 (8.7%) |
Married / partnered | 275 (72.4%) |
Divorcer / separated | 26 (6.8%) |
Widowed | 45 (11.8%) |
Not known | 1 (0.3%) |
Ethnicity | Â |
White British | 326 (85.8%) |
White Other | 27 (7.1%) |
Black | 12 (3.2%) |
Asian | 10 (2.6%) |
Other | 5 (1.3%) |
Religion | Â |
Atheist | 34 (8.9%) |
Christian | 305 (80.3%) |
Muslim | 7 (1.8%) |
Other | 21 (5.5%) |
Not known | 13 (3.4%) |
Highest educational level | Â |
Did not finish school | 27 (7.1%) |
Secondary school graduate | 183 (48.2%) |
College / technical qualification | 88 (23.2%) |
University first degree | 37 (9.7%) |
University higher degree | 21 (5.5%) |
Not known | 24 (6.3%) |
Occupation status | Â |
Working or student | 49 (12.9%) |
Not working | 47 (12.4%) |
Retired | 283 (74.5%) |
Not known | 1 (0.3%) |
ECOG performance status | Â |
0 | 133 (35.0%) |
1 | 146 (38.4%) |
2 | 64 (16.8%) |
3 | 36 (9.5%) |
4 | 1 (0.3%) |
Treatment status | Â |
Off treatment | 199 (52.4%) |
On treatment | 181 (47.6%) |
- High dose treatment with stem cell support | 5 (1.3%) |
- Chemotherapy / targeted therapy alone | 141 (37.1%) |
- Maintenance treatment | 35 (9.2%) |
Disease phase | Â |
Newly diagnosed | 79 (20.8%) |
Stable / plateau phase | 174 (45.8%) |
Relapsed / progressive | 127 (33.4%) |
Immunoglobulin type | Â |
IgG | 227 (59.7%) |
IgA | 79 (20.8%) |
IgM | 3 (0.8%) |
Light chain | 65 (17.1%) |
Non-secretory | 4 (1.1%) |
Not known | 2 (0.5%) |
ISS Stage at diagnosis | Â |
I | 105 (27.6%) |
II | 83 (21.8%) |
III | 81 (21.3%) |
Not known | 111 (29.2%) |
Months since diagnosis | Â |
0-12 | 101 (26.6%) |
13-24 | 63 (16.6%) |
25-36 | 31 (8.2%) |
37-48 | 36 (9.5%) |
Over 48 | 127 (33.4%) |
Not known | 22 (5.8%) |